Accolade Past Earnings Performance
Past criteria checks 0/6
Accolade's earnings have been declining at an average annual rate of -31.9%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 28.4% per year.
Key information
-31.9%
Earnings growth rate
30.9%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 28.4% |
| Return on equity | -22.4% |
| Net Margin | -24.1% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Accolade makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 414 | -100 | 162 | 99 |
| 30 Nov 23 | 388 | -123 | 163 | 98 |
| 31 Aug 23 | 380 | -142 | 166 | 99 |
| 31 May 23 | 371 | -155 | 170 | 98 |
| 28 Feb 23 | 363 | -460 | 175 | 99 |
| 30 Nov 22 | 358 | -464 | 188 | 98 |
| 31 Aug 22 | 350 | -401 | 189 | 97 |
| 31 May 22 | 336 | -417 | 190 | 95 |
| 28 Feb 22 | 310 | -123 | 186 | 84 |
| 30 Nov 21 | 275 | -93 | 138 | 75 |
| 31 Aug 21 | 230 | -132 | 110 | 65 |
| 31 May 21 | 194 | -85 | 78 | 55 |
| 28 Feb 21 | 170 | -51 | 63 | 50 |
| 30 Nov 20 | 156 | -48 | 57 | 45 |
| 31 Aug 20 | 147 | -50 | 57 | 43 |
| 31 May 20 | 140 | -49 | 56 | 42 |
| 29 Feb 20 | 133 | -51 | 56 | 42 |
| 30 Nov 19 | 123 | -56 | 55 | 43 |
| 28 Feb 19 | 95 | -56 | 43 | 36 |
| 28 Feb 18 | 77 | -61 | 43 | 31 |
Quality Earnings: 4NE1 is currently unprofitable.
Growing Profit Margin: 4NE1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4NE1 is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare 4NE1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4NE1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).
Return on Equity
High ROE: 4NE1 has a negative Return on Equity (-22.4%), as it is currently unprofitable.